GlassScriptPhysician profile
Rojee Ranjit Maharjan
NPI 1366004145
$6,248.56
in general payments reported to CMS, 2019-2025
30 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $429 · 2023: $1,354 · 2024: $1,736 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,848.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,187.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $777.26 | 2021-2025 | Farxiga, Wainua, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $743.44 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $490.65 | 2021-2025 | |
| Amgen INC. | $372.94 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $344.56 | 2023-2025 | |
| Abbvie INC. | $295.83 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $287.17 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $279.02 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $240.35 | 2021-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.06 | 2021-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $95.62 | 2023 | Arcalyst |
| Heartflow, INC. | $94.55 | 2024-2025 | |
| Exact Sciences Corporation | $92.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $89.49 | 2021-2024 | Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $81.26 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $78.90 | 2021 | |
| Scpharmaceuticals INC. | $68.98 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $55.81 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $53.82 | 2024 | Arcalyst |
| Mylan Specialty L.P. | $47.04 | 2021-2022 | |
| Cvrx, INC. | $45.93 | 2023 | Barostim Neo System |
| Janssen Scientific Affairs, LLC | $41.03 | 2023 | Xarelto |
| Cmp Pharma, INC. | $39.38 | 2023 | Tadliq, Norliqva, Carospir |
| Actelion Pharmaceuticals US, INC. | $29.90 | 2021-2022 | |
| Philips North America LLC | $23.06 | 2024 | (Ck4) Mcot |
| Aimmune Therapeutics, INC. | $22.05 | 2025 | Zenpep |
| Inspire Medical Systems, INC. | $21.48 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $21.10 | 2022 | |
| Ionis Pharmaceuticals, INC. | $17.48 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rojee Maharjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.